Compare Cadila Healthcare with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ASTRAZENECA PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE ASTRAZENECA PHARMA CADILA HEALTHCARE/
ASTRAZENECA PHARMA
 
P/E (TTM) x 28.8 138.0 20.8% View Chart
P/BV x 4.6 38.7 12.0% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 CADILA HEALTHCARE   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
ASTRAZENECA PHARMA
Mar-18
CADILA HEALTHCARE/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3521,278 27.6%   
Low Rs207883 23.4%   
Sales per share (Unadj.) Rs139.2228.4 61.0%  
Earnings per share (Unadj.) Rs11.810.4 113.5%  
Cash flow per share (Unadj.) Rs18.616.3 114.2%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs101.498.8 102.6%  
Shares outstanding (eoy) m1,023.7425.00 4,095.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.04.7 42.4%   
Avg P/E ratio x23.7104.2 22.8%  
P/CF ratio (eoy) x15.066.4 22.6%  
Price / Book Value ratio x2.810.9 25.2%  
Dividend payout %29.80-   
Avg Mkt Cap Rs m286,03327,008 1,059.1%   
No. of employees `00013.41.4 988.6%   
Total wages/salary Rs m24,1451,535 1,572.7%   
Avg. sales/employee Rs Th10,632.74,210.9 252.5%   
Avg. wages/employee Rs Th1,801.21,132.2 159.1%   
Avg. net profit/employee Rs Th898.5191.1 470.2%   
INCOME DATA
Net Sales Rs m142,5315,710 2,496.2%  
Other income Rs m1,139123 929.8%   
Total revenues Rs m143,6705,833 2,463.3%   
Gross profit Rs m24,198463 5,227.5%  
Depreciation Rs m6,965147 4,725.2%   
Interest Rs m3,4180-   
Profit before tax Rs m14,954438 3,414.2%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,198179 1,787.6%   
Profit after tax Rs m12,044259 4,648.4%  
Gross profit margin %17.08.1 209.4%  
Effective tax rate %21.440.8 52.4%   
Net profit margin %8.54.5 186.2%  
BALANCE SHEET DATA
Current assets Rs m87,1543,209 2,715.8%   
Current liabilities Rs m82,6942,070 3,995.8%   
Net working cap to sales %3.120.0 15.7%  
Current ratio x1.11.6 68.0%  
Inventory Days Days7172 98.7%  
Debtors Days Days9435 268.6%  
Net fixed assets Rs m133,236790 16,858.9%   
Share capital Rs m1,02450 2,048.0%   
"Free" reserves Rs m102,7332,419 4,246.4%   
Net worth Rs m103,7572,469 4,201.9%   
Long term debt Rs m32,1460-   
Total assets Rs m236,8664,605 5,143.2%  
Interest coverage x5.4NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.61.2 48.5%   
Return on assets %6.55.6 116.0%  
Return on equity %11.610.5 110.6%  
Return on capital %13.717.7 77.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,752300 17,610.4%   
Fx outflow Rs m14,5042,015 719.8%   
Net fx Rs m38,248-1,715 -2,229.7%   
CASH FLOW
From Operations Rs m25,05488 28,502.8%  
From Investments Rs m-10,123-94 10,815.2%  
From Financial Activity Rs m-10,942NA-  
Net Cashflow Rs m3,989-6 -69,982.5%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.3 0.3 2,766.7%  
FIIs % 5.9 15.7 37.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 9.1 120.9%  
Shareholders   44,069 12,856 342.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   NEULAND LABS  DR. REDDYS LAB  GSK PHARMA  ALEMBIC  PROCTER & GAMBLE HEALTH  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls Over 750 Points from Day's High; Metal and Realty Stocks Witness Selling(Closing)

After opening the day on a strong note, Indian share markets witnessed a sharp sell-off during closing hours today and ended lower.

Related Views on News

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 21, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS